Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 3, 2009, Pages 579-587

  Melander, Catherine ^a   Sallée, Marion ^a   Trolliet, Pierre ^b   Candon, Sophie ^c   Belenfant, Xavier ^d   Daugas, Eric ^e   Rémy, Phillipe ^f   Zarrouk, Virginie ^g   Pillebout, Evangéline ^h   Jacquot, Christian ⁱ   Boffa, Jean Jacques ^j   Karras, Alexandre ⁱ   Masse, Virginie ^a   Lesavre, Philippe ^a   Elie, Caroline ^a   Brocheriou, Isabelle ^k   Knebelmann, Bertrand ^a   Noël, Laure Hélène ^c   Fakhouri, Fadi ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Centre Hospitalier Intercommunal Andre Gregoire   (France)

^e BICHAT HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g BEAUJON HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j HÔPITAL TENON   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ETHNICITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HERPES ZOSTER; HUMAN; HYPOALBUMINEMIA; KIDNEY BIOPSY; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MALE; NAUSEA; NEGRO; NEUTROPENIA; OUTCOMES RESEARCH; PHARYNGITIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEPTIC SHOCK; VIRUS INFECTION; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECT; ETHNOLOGY; FRANCE; HOSPITALIZATION; IMMUNOLOGY; KIDNEY; KIDNEY FUNCTION TEST; MEMBRANOUS GLOMERULONEPHRITIS; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SELECTION; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; HYPOALBUMINEMIA; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; MALE; PATIENT SELECTION; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 66149099305     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04030808     Document Type: Article

References (29)

1. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals Int Med 135: 248-257, 2001 (Pubitemid 32799338)
2. Houssiau FA: Management of lupus nephritis: An update. J Am Soc Nephrol 15: 2694-2704, 2004
3. Austin HA, Illei GG: Membranous lupus nephritis. Lupus 14: 65-71, 2005
4. Houssiau FA, Ginzler EM: Current treatment of lupus nephritis. Lupus 17: 426-430, 2008
5. Christensen SR, Shlomchik MJ: Regulation of lupus-related autoantibody production and clinical disease by toll-like receptors. Sem Immunol 19: 11-23, 2007 (Pubitemid 46498753)
6. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: Idec-c2b8 (rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997 (Pubitemid 27392702)
7. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheumatic Dis 64: 913-920, 2005 (Pubitemid 40733918)
8. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Int Med 130: 461-470, 1999
10. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg J-E, Mariette X: Tolerance and efficacy of rituximab and changes in serum b cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheumatic Dis 66: 351-357, 2007 (Pubitemid 46579637)
11. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi L-M, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530, 2004 (Pubitemid 38130646)
12. Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, Fakhouri F: Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 52: 346-352, 2008 (Pubitemid 351978139)
13. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, Gonzalez-Amaro R: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 8: R83, 2006
14. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase i/ii dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589, 2004 (Pubitemid 39062719)
15. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54: 2970-2982, 2006
16. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following b cell depletion therapy is preceded by down-regulation of the t cell costimulatory molecule cd40 ligand: An open-label trial. Arthritis Rheum 52: 501-513, 2005 (Pubitemid 40216314)
17. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56: 1263-1272, 2007 (Pubitemid 46608651)
18. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M: A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: Immunological analysis of b cells, t cells and cytokines. Rheumatology (Oxford) 47: 821-827, 2008 (Pubitemid 351796367)
19. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Luning Prak ET, Kimberly R, Zhang Y, Eisenberg R: Variability in the biological response to anti-cd20 b-cell depletion in SLE. Ann Rheumatic Dis 67: 1724-1731, 2008
20. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA: Repeated b cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheumatic Dis 65: 942-945, 2006
21. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545, 2005 (Pubitemid 41742472)
22. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J: Six refractory lupus patients treated with rituximab: A case series. Arthritis Rheum 57: 538-542, 2007
23. Carroll RP, Brown F, Kerr PG: Anti-cd20 antibody treatment in refractory class iv lupus nephritis. Nephrol Dial Transplant 22: 291-293, 2007 (Pubitemid 46050375)
24. Silverman GJ: Therapeutic b cell depletion and regeneration in rheumatoid arthritis: Emerging patterns and paradigms. Arthritis Rheum 54: 2356-2367, 2006 (Pubitemid 44204995)
25. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ: The relationship of fcgammariiia genotype to degree of b cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455-459, 2003 (Pubitemid 36278014)
26. Van Den Berg L, Myhr KM, Kluge B, Vedeler CA: Fcgamma receptor polymorphisms in populations in Ethiopia and Norway. Immunology 104: 87-91, 2001 (Pubitemid 32955399)
27. Smith MR: Rituximab (monoclonal anti-cd20 antibody): Mechanisms of action and resistance. Oncogene 22: 7359-7368, 2003
28. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2007
29. Shirish R, Sangle RJD, Lubna Aslam, Myles J Lewis, Rose Wedgwood, Graham RV Hughes, Ian C. Abbs, David P. D'Cruz.: Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis: Poster Session: SLE. Boston, Congress of the American College of Rheumatology. 2007